Valneva Showcases Innovative Chikungunya Vaccine at World Vaccine Congress

On March 21, 2024, Valneva SE VALN, a French specialty vaccine company, made a noteworthy announcement. The firm revealed that it will present detailed information on its ground-breaking single-shot chikungunya vaccine, IXCHIQ®, at the 24th World Vaccine Congress in Washington D.C. Valneva's active participation extends beyond presentation; the company also aims to moderate a crucial roundtable discussion focusing on the challenges posed by Zika and chikungunya viruses.

A Focused Effort on Infectious Diseases

Valneva SE VALN, with its headquarters in Saint-Herblain, France, is at the forefront of tackling infectious diseases by developing prophylactic vaccines for diseases with unmet medical needs. Their commitment to addressing global health concerns is underscored by their efforts in researching and presenting on IXCHIQ®, which has the potential to protect against the mosquito-borne chikungunya virus.

Collaboration and Insight

Joining the conversation on vaccines, at the esteemed congress, will be Pfizer Inc. PFE. As an American multinational pharmaceutical and biotechnology giant, Pfizer brings a wealth of knowledge and experience in the development and commercialization of medicines and vaccines. Their portfolio, spanning immunology, oncology, cardiology, to neurology, complements Valneva's specialized endeavors in vaccine innovation.

Valneva, Pfizer, Vaccine